300 related articles for article (PubMed ID: 11043500)
1. Measurement of soluble adhesion molecules in primary Raynaud's phenomenon and in Raynaud's phenomenon secondary to connective tissue diseases.
Brevetti G; De Caterina M; Martone VD; Corrado S; Silvestro A; Spadaro G; Scopacasa F
Int J Clin Lab Res; 2000; 30(2):75-81. PubMed ID: 11043500
[TBL] [Abstract][Full Text] [Related]
2. Systemic sclerosis-related Raynaud's phenomenon: effects of iloprost infusion therapy on serum cytokine, growth factor and soluble adhesion molecule levels.
Mittag M; Beckheinrich P; Haustein UF
Acta Derm Venereol; 2001; 81(4):294-7. PubMed ID: 11720181
[TBL] [Abstract][Full Text] [Related]
3. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
Rychlik-Golema W; Mastej K; Adamiec R
Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.
Coleiro B; Marshall SE; Denton CP; Howell K; Blann A; Welsh KI; Black CM
Rheumatology (Oxford); 2001 Sep; 40(9):1038-43. PubMed ID: 11561116
[TBL] [Abstract][Full Text] [Related]
5. Effect of total-body cold exposure on plasma concentrations of von Willebrand factor, endothelin-1 and thrombomodulin in systemic lupus erythematosus patients with or without Raynaud's phenomenon.
Matsuda J; Tsukamoto M; Gohchi K; Saitoh N; Miyajima Y; Kazama M
Acta Haematol; 1992; 88(4):189-93. PubMed ID: 1337960
[TBL] [Abstract][Full Text] [Related]
6. Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon.
Lau CS; McLaren M; Mackay I; Belch JJ
Ann Rheum Dis; 1993 Jun; 52(6):443-8. PubMed ID: 8323396
[TBL] [Abstract][Full Text] [Related]
7. Increased factor VIII/von Willebrand factor antigen and von Willebrand factor activity in scleroderma and in Raynaud's phenomenon.
Kahaleh MB; Osborn I; LeRoy EC
Ann Intern Med; 1981 Apr; 94(4 pt 1):482-4. PubMed ID: 6782927
[TBL] [Abstract][Full Text] [Related]
8. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study.
Denton CP; Howell K; Stratton RJ; Black CM
Clin Exp Rheumatol; 2000; 18(4):499-502. PubMed ID: 10949727
[TBL] [Abstract][Full Text] [Related]
9. Progressive vascular damage in hypertension is associated with increased levels of circulating P-selectin.
Verhaar MC; Beutler JJ; Gaillard CA; Koomans HA; Fijnheer R; Rabelink TJ
J Hypertens; 1998 Jan; 16(1):45-50. PubMed ID: 9533416
[TBL] [Abstract][Full Text] [Related]
10. Blood viscosity and local response to cold in primary Raynaud's phenomenon.
Jahnsen T; Nielsen SL; Skovborg F
Lancet; 1977 Nov; 2(8046):1001-2. PubMed ID: 72898
[TBL] [Abstract][Full Text] [Related]
11. Evidence for the regulation of levels of plasma adhesion molecules by proinflammatory cytokines and their soluble receptors in type 1 diabetes.
Mohamed-Ali V; Armstrong L; Clarke D; Bolton CH; Pinkney JH
J Intern Med; 2001 Nov; 250(5):415-21. PubMed ID: 11887976
[TBL] [Abstract][Full Text] [Related]
12. [Etiological profile of secondary Raynaud's phenomenon in an internal medicine department. About 121 patients].
Ben Salem T; Tougorti M; Bziouech S; Lamloum M; Khanfir M; Ben Ghorbel I; Houman MH
J Med Vasc; 2018 Feb; 43(1):29-35. PubMed ID: 29425538
[TBL] [Abstract][Full Text] [Related]
13. How to classify Raynaud's phenomenon. Long-term follow-up study of 73 cases.
Priollet P; Vayssairat M; Housset E
Am J Med; 1987 Sep; 83(3):494-8. PubMed ID: 3661586
[TBL] [Abstract][Full Text] [Related]
14. A pathogenic role for endothelin in Raynaud's phenomenon?
Bottomley W; Goodfield M
Acta Derm Venereol; 1994 Nov; 74(6):433-4. PubMed ID: 7701873
[TBL] [Abstract][Full Text] [Related]
15. Circulating adhesion molecules in patients with vibration-induced white finger.
Kurozawa Y; Nasu Y
Angiology; 2000 Dec; 51(12):1003-6. PubMed ID: 11132991
[TBL] [Abstract][Full Text] [Related]
16. [Raynaud's disease and Raynaud's phenomenon in connective tissue diseases].
Sicińska J; Rudnicka L
Pol Arch Med Wewn; 2002 Oct; 108(4):1011-22. PubMed ID: 12642947
[No Abstract] [Full Text] [Related]
17. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.
Torley HI; Madhok R; Capell HA; Brouwer RM; Maddison PJ; Black CM; Englert H; Dormandy JA; Watson HR
Ann Rheum Dis; 1991 Nov; 50(11):800-4. PubMed ID: 1722967
[TBL] [Abstract][Full Text] [Related]
18. Soluble intercelluar adhesion molecule-1, E-selectin, vascular cell adhesion molecule-1 and von Willebrand factor in stroke.
Blann A; Kumar P; Krupinski J; McCollum C; Beevers DG; Lip GY
Blood Coagul Fibrinolysis; 1999 Jul; 10(5):277-84. PubMed ID: 10456619
[TBL] [Abstract][Full Text] [Related]
19. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon.
Zamora MR; O'Brien RF; Rutherford RB; Weil JV
Lancet; 1990 Nov; 336(8724):1144-7. PubMed ID: 1978025
[TBL] [Abstract][Full Text] [Related]
20. Soluble circulating cell adhesion molecules in haemolytic uraemic syndrome.
Inward CD; Pall AA; Adu D; Milford DV; Taylor CM
Pediatr Nephrol; 1995 Oct; 9(5):574-8. PubMed ID: 8580013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
